News

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-04-2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data... read more 

Goals

Our objective is to become a leader in the development of end stage blood cancer treatments by leveraging our development, clinical and regulatory experience to bring to the market innovative products that target significant unmet medical needs. Our strategy is to rapidly advance our lead blood cancer products in the European Union, the United States and Canada targeting orphan indications. We intend to strengthen our relationships with leading transplantation specialists and to retain independent marketing rights to drive direct sales of our blood cancer products to transplantation centers.

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51